Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332100 | 0.85 | GFER (0.42) | IDO1TAAR1MAOBHTR3ACYP2A6 | |
| SCHEMBL9168877 | 0.84 | IDO1 (0.56) | IDO1TAAR1MAOBAOC3HTR3E | |
| SCHEMBL2135113 | 0.82 | TAAR1 (0.68) | IDO1TAAR1MAOBAOC3HTR3E | |
| SCHEMBL7618913 | 0.80 | IDO1 (0.52) | IDO1TAAR1MAOBAOC3HTR3E | |
| SCHEMBL307618 | 0.77 | — | — | |
| SCHEMBL18050371 | 0.77 | TAAR1 (0.62) | IDO1TAAR1MAOBAOC3HTR3E | |
| SCHEMBL10365734 | 0.77 | IGF1R (0.64) | IDO1TAAR1MAOBAOC3HTR3E | |
| SCHEMBL11026456 | 0.74 | IDO1 (0.36) | IDO1TAAR1 | |
| SCHEMBL130660 | 0.74 | TAAR1 (0.59) | IDO1TAAR1MAOBAOC3HTR3E | |
| SCHEMBL1115439 | 0.74 | IGF1R (0.61) | IDO1TAAR1MAOBAOC3HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812406-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-12 | — | — | EP | disclosed |
| EP-1805147-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-8067420-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067420-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8012984-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012984-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| US-20110003759-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| WO-1999005114-A2 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
| EP-0332331-B1 | Thiazolidinedione hypoglycemic agents | PFIZER (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5223522-A | Anticholesterol agents | PFIZER INC. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5120754-A | Anticholesterol and antidiabetic agents | PFIZER INC. (US) | 1992-06-09 | — | — | US | disclosed |
| US-5061717-A | ANTICHOLESTEROL AGENTS | PFIZER INC. (US) | 1991-10-29 | — | — | US | disclosed |
| EP-0301421-B1 | SULFUR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND MEDICINES | Roche Diagnostics GmbH (DE) | 1991-08-28 | — | — | EP | disclosed |
| WO-1989008650-A1 | THIAZOLIDINEDIONE HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332331-A2 | Thiazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| EP-0301421-A2 | Sulfur compounds, process for their preparation and medicines | Roche Diagnostics GmbH (DE) | 1989-02-01 | — | — | EP | disclosed |
| US-4458079-A | BACTERICIDES, FUNGICIDES | BRISTOL-MYERS COMPANY (US) | 1984-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MC1R, MCHR2 | IDO1 543/4885TAAR1 32/4885MAOB 311/4885 |
| US-20110003759-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MCHR2, MC1R | IDO1 419/4885TAAR1 29/4885MAOB 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.